Advertisement
Canada markets closed

  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.09%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    87,300.55
    -980.72 (-1.11%)
     

  • CMC Crypto 200

    1,328.16
    -68.38 (-4.90%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     

  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Helix BioPharma Corp. Announces CAR-T Poster Presentation at the AACR Conference

CAR-T Cells Harboring Camelid Single Domain Antibody as Targeting Agent to CEACAM6 Antigen in Pancreatic Cancer

Marketwired

AURORA, ON--(Marketwired - September 01, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company's poster entitled: CAR-T Cells Harboring Camelid Single Domain Antibody as Targeting Agent to CEACAM6 Antigen in Pancreatic Cancer has been accepted for presentation at the AACR Conference on Tumor Immunology and Immunotherapy taking place on October 20th through to the 23rd, 2016 at the Boston Marriott Copley Place in Boston, Massachusetts. A copy of the poster presentation will be made available on the Company's website.

This poster presentation reports Helix's first proof-of-principle study applying camelid single domain antibody in making Chimeric Antigen Receptor T Cells ("CAR-T"). The poster describes preliminary cell line and animal data that explore the potential of using this construct for pancreatic cancer. This study was conducted using camelid single domain antibody obtained from our collaboration with National Research Council of Canada (NRC).

"We are delighted to continue our collaboration with NRC and testing a candidate selected from their single domain library. This opportunity to present data from our research and development work will form the basis for advancing our first CAR-T solid tumor candidate swiftly towards clinical testing," said Dr. Sven Rohmann, CEO of Helix.

About Helix BioPharma Corp.
Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".

ADVERTISEMENT

About National Research Council of Canada

National Research Council is the Government of Canada's premier organization for research and development. NRC partners with Canadian industry to take research impacts from the lab to the marketplace, where people can experience the benefits. This market-driven focus delivers innovation faster, enhances people's lives and addresses some of the world's most pressing problems. NRC is responsive, creative and uniquely placed to partner with Canadian industry, to invest in strategic R&D programming that will address critical issues for our future.

Investor Relations
Helix BioPharma Corp.
3-305 Industrial Parkway South
Aurora, Ontario, L4G 6X7
Tel: 905 841-2300
Email: ir@helixbiopharma.com

Forward-Looking Statements and Risks and Uncertainties
This news release contains certain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including, without limitation, those relating to the potential of using camelid single domain antibody in making CAR-T for pancreatic cancer, our collaboration with the national Research Council of Canada, and the advancing of the Company's first CAR-T solid tumor candidate toward clinical testing, which may be identified by words including, without limitation, "will", "may", "anticipated", "swiftly" and other similar expressions, are intended to provide information about management's current plans and expectations.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include those described in Helix's most recent Annual Report, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.